During the third quarter, Bank Pictet & Cie Europe AG increased its stake in Gilead Sciences by 502.8%, acquiring an additional 12,752 shares to reach a total holding of 15,288 shares valued at $1.697 million as of its latest SEC filing. Invesco Ltd. grew its position by 33.5% in the second quarter to 13.52 million shares, now worth $1.499 billion after adding 3.39 million shares. Similarly, Sivik Global Healthcare LLC boosted its stake by 25% to 50,000 shares ($5.544 million), One Wealth Advisors LLC increased by 34.8% to 9,163 shares ($1.016 million), and Lombard Odier Asset Management Switzerland SA added 10,535 shares to reach 53,312 shares ($5.911 million). Jump Financial LLC also established a new position valued at approximately $6.99 million. Institutional investors now control 83.67% of the company’s outstanding shares.

In its third‐quarter results, Gilead Sciences reported earnings per share of $2.47, surpassing consensus estimates by $0.31, and delivered revenue of $7.77 billion, a 3.0% increase year‐over‐year versus the expected $7.42 billion. The company achieved a net margin of 27.88% and a return on equity of 51.86%. Management set full-year 2025 guidance at $8.05 to $8.25 in adjusted EPS, while analysts project $7.95 for the current fiscal year. The firm’s operating cash flow remains a key indicator of its ability to fund research, pay expenses and return capital to shareholders.

A total of 28 analysts have issued ratings on Gilead Sciences stock, including two Strong Buy assessments, 22 Buy ratings and four Hold ratings, resulting in an average ‘Moderate Buy’ consensus. Citigroup raised its price target from $125 to $135 with a Buy rating, Rothschild & Co Redburn lifted its target from $143 to $153, Goldman Sachs nudged its objective from $108 to $110 while maintaining a Neutral rating, and Scotiabank initiated coverage with a Sector Outperform rating and a $140 target. The average analyst price target stands at $131.68, reflecting anticipation of further upside potential.

Gilead Sciences declared and paid a quarterly dividend of $0.79 per share on December 30, representing a $3.16 annualized payout and a yield of 2.6%, with a payout ratio of 48.99%. Insider activity over the past quarter included the sale of 3,000 shares by CFO Andrew D. Dickinson at an average price of $122.00 for proceeds of $366,000 and the sale of 5,000 shares by Director Jeffrey Bluestone at an average of $125.08 for $625,400. Insiders have sold a total of 136,257 shares valued at $16.86 million during the period, with insider ownership now at 0.27%.